Clinical Trials Logo

Gastrointestinal Tolerance clinical trials

View clinical trials related to Gastrointestinal Tolerance.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05827198 Not yet recruiting - Clinical trials for Gastrointestinal Tolerance

Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies

Start date: September 12, 2023
Phase: N/A
Study type: Interventional

This study is a randomized, single-blind, crossover trial aiming at evaluating the gastrointestinal tolerance of a sugar replacer blend (inulin + soluble corn fiber + erythritol) at 3 different doses

NCT ID: NCT04243187 Not yet recruiting - Clinical trials for Gastrointestinal Disease

Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

The oligosaccharide content (raffinose, stachyose, and verbascose) in legumes would be responsible for gastrointestinal symptoms (bloating, pain, meteorism), associated with its consumption. We would evaluate consumption of 3 varieties of chilean native beans, and evaluate gastrointestinal symptoms produced along with expired H2 test, to correlate this with the amount of oligosaccharide content.

NCT ID: NCT04100460 Not yet recruiting - Clinical trials for Gastrointestinal Tolerance

A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).

Start date: September 2019
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the effect on Arabinoxylan on gastrointestinal (GI) tolerance, bowel habits, and microbiota in adults. The study is a randomized, placebo-controlled, crossover, single-center trial with 3 study periods separated by minimum 2-week washout periods. 45 healthy adults will be recruited for the trial. Participants will be required to drink a beverage twice a day for 3 weeks during each study period. The beverage will contain either approximately 7.25 grams of Arabinoxylan leaf fiber extract per day, or approximately 14.5 grams of Arabinoxylan leaf fiber extract per day, or will not contain any Arabinoxylan (control). Subjects will record their bowel movements daily, fill out daily questionnaires about their gastrointestinal systems, and record their food intake at specified times during the study. Stool samples will also be collected prior to and at the end of each study period for analysis of bacteria composition.